Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | PHASE1 | ACTIVE NOT_RECRUITING | 40 | — | — | Mar 28, 2024 | Jul 1, 2028 | Apr 6, 2026 | 5 | United States |
To evaluate the safety and tolerability of the TIL regimen that occurs from the start of TIL infusion and up to 30 days after TIL infusion per CTCAE.
| Arm | Type | Description |
|---|---|---|
| Rhabdomyosarcoma (RMS) | EXPERIMENTAL | - |
| Ewing Sarcoma (EWS) | EXPERIMENTAL | - |
| Primary Central Nervous System Tumor | EXPERIMENTAL | - |
| Melanoma | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LN-145/LN-144 | BIOLOGICAL | A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. |
Inclusion Criteria: 1. Participant is ≥ 8 kg and ≤ 21 years of age at the time of informed consent and assent. 2. Histologically or cytologically confirmed recurrent or refractory solid tumor (Rhabdomyosarcoma, Ewing sarcoma, primary CNS malignancies, melanoma) after standard therapy which has fail...